Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ricrolin TE vs Standard CXL for Progressive Keratoconus
NCT02349165Completed
- Start
- May 2011
- Primary completion
- Sep 2014
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of Ricrolin in keratoconus (2 arms). Primary endpoint: Clinical stabilisation of keratoconus at 1 year. Started May 2011; status: completed.
02
Drugs
Ricrolin
03
Conditions
keratoconus
Beyond the preview
Go deeper on NCT02349165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02349165.